Timber Pharmaceuticals Stock Price

0.0499 (2.7%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Timber Pharmaceuticals Inc TMBR AMEX Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
0.0499 2.7% 1.8999 1.83 1.945 1.85 1.85 19:16:55
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,140 282,443 $ 1.89 $ 533,908 762,366 1.75 - 4.17
Last Trade Time Type Quantity Stock Price Currency
18:30:00 100 $ 1.8999 USD

Timber Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 22.51M 11.85M 11.85M $ 270.54k $ - -0.26 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
418.98k $ - 0.00% 3.00 -

more financials information »

Timber Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TMBR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.881.9451.811.87239,6050.01991.06%
1 Month2.152.891.752.07776,131-0.2501-11.63%
3 Months3.383.981.752.431,013,586-1.48-43.79%
6 Months4.114.171.752.441,005,867-2.21-53.77%
1 Year4.114.171.752.441,005,867-2.21-53.77%
3 Years4.114.171.752.441,005,867-2.21-53.77%
5 Years4.114.171.752.441,005,867-2.21-53.77%

Timber Pharmaceuticals Description

Timber Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. It is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), tuberous sclerosis complex (TSC), and localized scleroderma. Its development pipeline includes TMB-001 (Topical Isotretinoin), TMB-002 (Topical Rapamycin), and TMB-003 (Topical / Subcutaneous ET-A Receptor Antagonist).

Your Recent History
Timber Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.